dihexa wiki Dihexa | c-Met/HGFR | TargetMol

If regulatory submissions proceed as expected, the earliest plausible timeline for a market authorisation decision in the UK or Europe would be 2026 or 2027 though this is subject to the pace of regulatory review, the completeness of the submission package, and any additional data requests from the MHRA or EMA

Pflgers Arch Eur J Physiol 464:601611

If an underlying condition is responsible (liver disease, kidney disease, myeloproliferative disorder, or cancer), treating the underlying condition is the priority

Many patients pair it with functional medicine, hormone therapy, or IV therapy as part of a broader plan

This granular control helps some users manage side effects more effectively